The Effect of Pregabalin on the required dose of the anesthetic vapor Sevoflurane to achieve immobility

The effect of pregabalin on the minimal alveolar concentration of sevoflurane - MAC Sevo Pregabalin

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2017-001439-37-AT

Enrollment

Registered

2019-08-23

Start date

2019-09-16

Completion date

Unknown

Last updated

2019-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

This study aims to investigate the effect of clinically used doses of Pregabalin on the minimum alveolar concentration of sevoflurane to provide more information to clinicians using this adjunctive drug in the perioperative setting.

Interventions

Trade Name: Lyrica Pharmaceutical Form: Capsule, hard INN or Proposed INN: Pregabalin CAS Number: 148553-50-8 Current Sponsor code: EU/1

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: We will include only adult patients aged 30-65 years of the ASA classes 1-3 and a BMI between 18.5 and 30, undergoing elective surgery under general anaesthesia with a skin incision of at least 3 cm at the trunk. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 75 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Patients not able to understand the study procedure, patients needing premedication with sedative or analgesic drugs, patients with a history of chronic pain, patients in whom inhalational induction of anaesthesia is contraindicated and patients with a known allergy to one of the study medications and pregnant or breastfeeding patients cannot be included in the study.

Design outcomes

Primary

Measure	Time frame
Main Objective: This study aims to investigate the effect of clinically used doses of Pregabalin on the minimum alveolar concentration of sevoflurane to provide more information to clinicians using this adjunctive drug in the perioperative setting. ; Secondary Objective: This study examines the effect of Pregabalin on the Bispectralindex during Sevoflurane Anesthesia ;Primary end point(s): Response to skin incision;Timepoint(s) of evaluation of this end point: At skin incision	—

Measure

Time frame

Main Objective: This study aims to investigate the effect of clinically used doses of Pregabalin on the minimum alveolar concentration of sevoflurane to provide more information to clinicians using this adjunctive drug in the perioperative setting. ; Secondary Objective: This study examines the effect of Pregabalin on the Bispectralindex during Sevoflurane Anesthesia ;Primary end point(s): Response to skin incision;Timepoint(s) of evaluation of this end point: At skin incision

—

Secondary

Measure	Time frame
Secondary end point(s): Bispectral Index before and after skin incision;Timepoint(s) of evaluation of this end point: immediately before and after skin incision	—

Countries

Austria

Contacts

Public ContactDepartment of General Anaesthesia

Medical University of Vienna

thomas.hamp@meduniwien.ac.at

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026